If you’re weighing IV ketamine against Spravato, here’s the short answer: there isn’t a single treatment that’s better for everyone. Spravato is FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation, administered as a nasal spray under a certified REMS monitoring protocol. IV ketamine is administered intravenously and used off-label for treatment-resistant depression, PTSD, anxiety, and related concerns after a full clinical evaluation. Which one makes sense for you depends on your diagnosis, your treatment history, your insurance situation, and what your evaluation shows, not a one-size-fits-all recommendation.

Patients ask Parker Neuroscience to compare the two almost as often as they ask about either treatment individually, so here’s how the decision actually gets made.

What Is Spravato?

Spravato is the brand name for esketamine, an FDA-approved intranasal medication for eligible adults with treatment-resistant depression. It’s administered under a REMS program in a certified clinical setting, and you remain under direct supervision for a minimum of two hours after each dose. Because it has FDA approval for these specific diagnoses, it also carries real insurance coverage potential, which isn’t something every ketamine-based option can say. You can read more about eligibility and what a session involves on our Spravato page.

What Is IV Ketamine?

IV ketamine is delivered intravenously, which allows for more precise, real-time dosing adjustments during the session. It’s used off-label for treatment-resistant depression, PTSD, anxiety, and related psychiatric concerns, meaning it hasn’t gone through the same FDA approval process as Spravato for these uses, even though many patients respond well to it. Details on what a full IV ketamine therapy series looks like are on that page.

Where They Actually Differ

Both treatments share a related mechanism, but they’re clinically distinct in a few practical ways that matter when you’re deciding between them:

FDA status. Spravato has completed the large-scale trials required for FDA approval in treatment-resistant depression and MDD with acute suicidal ideation. IV ketamine’s psychiatric use remains off-label.

Administration. Spravato is a self-administered nasal spray under direct clinical observation. IV ketamine is administered intravenously by our clinical team, which allows more control over the dose in real time.

Monitoring window. Spravato requires a minimum two-hour observation period after dosing as part of its REMS protocol. IV ketamine sessions are also fully monitored, though the structure of that monitoring differs since it’s not governed by the same federal program.

Insurance and cost. This is usually the deciding factor for patients, so it’s worth stating plainly. Parker Neuroscience is in-network with UnitedHealthcare/Optum for Spravato treatment, with additional insurance contracts currently in progress. IV ketamine is offered as a self-pay service. We’re not able to accept Medicare or Medicaid for either treatment. Full details, along with our waitlist for patients whose insurance we don’t take yet, are on our insurance and payment options page.

How Parker Neuroscience Decides Which to Recommend

Neither option is categorically better. When a patient asks which one is right for them, Dr. Parker looks at the same things every time: diagnosis, prior treatment history, current medications, and overall safety profile. Someone with a treatment-resistant depression diagnosis who meets Spravato’s FDA-approved criteria and wants the insurance pathway is often a strong fit there. Someone whose clinical picture falls outside those specific diagnostic criteria, or who has already explored Spravato without the response they’d hoped for, may be a better fit for treatment-resistant depression care built around IV ketamine instead. That evaluation is the actual starting point of care, not a formality before it.

What the Research Says

Because this comparison comes up so often clinically, it’s also an active area of research. A Yale-led comparative study is currently working to answer, in a real-world, randomized setting, how the two options actually compare in effectiveness, something that hasn’t had strong head-to-head data until now.

What to Expect Either Way

Whichever option ends up being the right fit, the front half of your experience looks similar: a thorough evaluation, baseline vitals, a private and monitored treatment setting, and a ride home arranged in advance. If you want the full walk-through of what a session actually feels like, that’s covered in our first appointment guide.

Questions related to this one

Is Spravato more effective than IV ketamine? Neither is categorically more effective. Spravato has completed the large-scale trials required for FDA approval in treatment-resistant depression and MDD with acute suicidal ideation. IV ketamine’s psychiatric use remains off-label, though many patients respond well to it. Your evaluation is what determines which option gives you the better chance of meaningful improvement.

Does insurance cover IV ketamine, or just Spravato? At Parker Neuroscience, we’re in-network with UnitedHealthcare/Optum for Spravato treatment, with additional insurance contracts in progress. IV ketamine is currently offered as a self-pay service. We’re not able to accept Medicare or Medicaid for either treatment.

Can I switch from one treatment to the other? Yes. If your evaluation, or your response over time, suggests a different option may serve you better, that’s a conversation we can have. Starting with one option doesn’t lock you into it.

Which treatment works faster? Both are generally faster-acting than traditional oral antidepressants, which can take weeks to show an effect. How quickly you personally notice a difference still varies, some patients notice change within the first few sessions, while for others it builds gradually across a series, regardless of which treatment they’re using.